Galapagos NV (GLPG)

Market Cap	1.76B
Revenue (ttm)	290.09M
Net Income (ttm)	230.13M
Shares Out	65.94M
EPS (ttm)	3.50
PE Ratio	7.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	159,346
Open	26.27
Previous Close	26.37
Day's Range	26.14 - 27.00
52-Week Range	24.16 - 42.46
Beta	0.06
Analysts	Hold
Price Target	30.75 (+14.91%)
Earnings Date	Feb 12, 2025

About GLPG

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 6, 2005
• Employees: 1,123
• Stock Exchange: NASDAQ
• Ticker Symbol: GLPG
• Website: https://www.glpg.com

Financial Performance

Financial numbers in EUR

Analyst Forecast

According to 4 analysts, the average rating for GLPG stock is "Hold." The 12-month stock price forecast is $30.75, which is an increase of 14.91% from the latest price.

Price Target

$30.75

(14.91% upside)

Analyst Consensus: Hold